Anna Maria Ceravolo
Acute Care · Birmingham, ALNPI 1164050027
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 380 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $4,150, more than ten times the $56 reported in 2023. Among acute care clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 380 payments — averaging $19.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- UCB, Inc.$1K
- Neurelis, Inc.$530
- Pfizer$511
- Axsome Therapeutics, Inc.$484
- Merz Pharmaceuticals, LLC$410
- plus $3K from 24 others
What the payments were for
- Food & beverage$7,34099%
- Education$771%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 93 | $1,332 |
| UCB, Inc. | 73 | $1,169 |
| Neurelis, Inc. | 26 | $530 |
| Pfizer | 23 | $511 |
| Axsome Therapeutics, Inc. | 22 | $484 |
| Merz Pharmaceuticals, LLC | 15 | $410 |
| SK Life Science, Inc. | 11 | $334 |
| Lundbeck LLC | 11 | $272 |
| AstraZeneca(2 entities) | 12 | $254 |
| Eisai Inc. | 8 | $233 |
| Biogen | 9 | $214 |
| Argenx US, Inc. | 12 | $211 |
| Lilly USA, LLC | 12 | $208 |
| Johnson & Johnson | 5 | $187 |
| Catalyst Pharmaceuticals, Inc. | 8 | $176 |
| Acadia Pharmaceuticals Inc | 7 | $155 |
| Aucta Pharmaceuticals, Inc. | 6 | $128 |
| Ipsen Biopharmaceuticals, Inc | 5 | $95 |
| Jazz Pharmaceuticals Inc. | 3 | $79 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $64 |
| Amgen | 3 | $64 |
| Teva Pharmaceuticals USA, Inc. | 3 | $60 |
| Elutia, Inc. | 1 | $56 |
| Kyowa Kirin, Inc. | 3 | $55 |
| Averitas Pharma Inc. | 2 | $43 |
| Monteris Medical Corporation | 1 | $24 |
| Scilex Pharmaceuticals Inc. | 1 | $20 |
| Medtronic | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Kedrion Biopharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,417 in reported general payments places this provider in the 90th percentile of 711 acute care providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 18 | $36,234 |
| UbrelvyUbrogepant | 12 | $14,152 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 16 | $11,298 |
| Emgality PenGalcanezumab-Gnlm | 11 | $7,414 |
| Rasagiline Mesylate | 11 | $3,364 |
| Sumatriptan Succinate | 11 | $2,121 |
| Duloxetine Hcl | 23 | $1,418 |
| Levetiracetam ErLevetiracetam | 12 | $740 |
| Atorvastatin Calcium | 20 | $542 |
| Ropinirole Hcl | 16 | $478 |
| Baclofen | 22 | $452 |
| Memantine Hcl | 19 | $428 |
| Ondansetron OdtOndansetron | 29 | $401 |
| Zonisamide | 16 | $323 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 14 | $307 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $511 | $36,23418 claims |
| AbbVieUbrelvy | $1,332 | $14,15212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 711 acute care providers in Alabama.
Other acute care in Birmingham
- Coretta CollinsBirmingham$77K
- Cameron StephensonBirmingham$13K
- Jonathan McCraryBirmingham$13K
- Michelle PriceBirmingham$13K
- Melissa FrenchBirmingham$13K
- Jaime CannonBirmingham$12K
- Kaci WeaverBirmingham$11K
- Alexandra GlennBirmingham$11K
- Bridget CrainBirmingham$10K
- Rachel CookBirmingham$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.